This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Adam Feuerstein

Senior Columnist

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.


Feuerstein graduated from Emory University with a bachelor's degree in political science.


Adam Feuerstein
By This Author:
Page 3 of 580

Seattle Genetics Makes Case for Expanded Use of Adcetris as Lymphoma Maintenance Therapy

By Adam Feuerstein

New Adcetris data are from a phase III study known AETHERA are being presented in full at the American Society of Hematology (ASH) annual meeting underway in San Francisco.

11:00AM 12/06/14

Amgen Hopes Sentiment Swings Sweeter for Myeloma Drug at Key Blood Cancer Meeting

By Adam Feuerstein

Scientists and investors are getting their first detailed look this weekend at a large study of Amgen's multiple myeloma drug Kyprolis.

11:00AM 12/06/14

Biotech Stock Mailbag: Aethlon Medical, Oxigene, Sarepta

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health care.

06:00AM 12/05/14

Array Biopharma Regains Rights to Cancer Drug From Novartis

By Adam Feuerstein

The re-acquisition of binimetinib by Array was expected after Novartis announced in April a business swap with GlaxoSmithKline GSK which included the acquisition of Glaxo's cancer drug business.

04:01PM 12/03/14

Amgen Wins U.S. Approval for Immunotherapy Against Leukemia

By Adam Feuerstein

Wednesday's approval of Blincyto comes more than five months ahead of the expected May 19, 2015 approval decision date.

01:31PM 12/03/14

Puma Forced to Delay Breast Cancer FDA Submission Due to New Safety Data Requirement

By Adam Feuerstein

Puma Biotechnology is pushing back an approval filing for its breast cancer drug neratinib into 2016 -- almost a one year delay.

04:34PM 12/02/14

Five Biotech Firms Whose Stock-Promoting Efforts Didn't Pay Off

By Adam Feuerstein

Let's look back at the stock performance of biotech companies issuing the worst, most pandering press releases from January 2014.

11:00AM 12/02/14

Avanir Fetches $3.5B From Japan's Otsuka for Reformulated Cough Syrup

By Adam Feuerstein

The Japanese drugmaker is trying to shore up its product pipeline ahead of April 2015 when patents on its best-selling schizophrenia drug Abilify expire.

09:13AM 12/02/14

Future of Exelixis Cancer Drug Dims Further With Second Failed Prostate Cancer Study

By Adam Feuerstein

All too often, promising results from phase II studies don't pan out when larger, confirmatory phase III studies are conducted. That's exactly what happened to Exelixis.

11:37AM 12/01/14

December's Essential, Stock-Moving Biotech Events Explained While Eating Turkey

By Adam Feuerstein

A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for health care investors.

06:00AM 11/26/14

Page 3 of 580

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs